Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Quest Diagnostics

What Are Wall Street Analysts' Target Price for Quest Diagnostics Stock?

Despite Quest Diagnostics’ underperformance relative to the broader S&P 500 Index over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart

Quest Diagnostics' Quarterly Earnings Preview: What You Need to Know

With Quest Diagnostics gearing up to release its third-quarter earnings later this month, analysts expect a low single-digit earnings growth.

Barchart

Quest Diagnostics Stock: Is Wall Street Bullish or Bearish?

As Quest Diagnostics underperformed relative to the S&P 500 Index over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Quest Diagnostics’ Q2 2024 Earnings: What to Expect

As Quest Diagnostics gears up to unveil its second-quarter earnings results, Wall Street analysts remain cautiously optimistic about the stock’s prospects.

Barchart

Should You Be Able To Take an Alzheimer's Test at Home?

Plus, an AI-generated version of the same article

Reason

You can help Google with its latest Fitbit study on metabolic health

Fitbit and Pixel Watch owners can participate in a metabolic health study, which involves providing digital health data and a blood sample.

Android Central

Workers test positive for weed at highest rate since 1997

Amphetamine use is on the rise as well.

Fortune

Read news from The Economist, FT, and more,
with one subscription

Legal pot raises questions about the future of workplace drug policies in Missouri

ST. LOUIS — While marijuana legalization proponents celebrated victory in their fight for recreational cannabis, Missouri business owners were phoning their lawyers.

St. Louis Post-Dispatch

Masimo's (MASI) Q2 Earnings Surpass Estimates, Margins Down

Masimo Corporation (NASDAQ: MASI) delivered adjusted earnings per share (ETF:EPS) of $1.35 in the second quarter of 2022, up 43.6% year over year. The figure surpassed the Zacks Consensus Estimate by 13.5%.

Benzinga

US boosts monkeypox testing, 142 cases confirmed

The Biden administration has started shipping testing kits for monkeypox to commercial laboratories, in a bid to speed diagnostic tests for suspected infections for the virus that has already infected at least 142 people in the U.S. The Centers for Disease Control and Prevention is sending tests to commercial labs,…

The Independent UK

5 Value Stocks To Watch In The Healthcare Sector

The Meaning Behind Value Stocks

Benzinga

5 Value Stocks To Watch In The Healthcare Sector

What Defines a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.

Benzinga

Quest Diagnostics' COVID-19 Testing Sales Decline 28% In Q1; Lifts FY22 EPS Guidance

Quest Diagnostics Inc (NYSE:DGX) posted a better-than-expected Q1 FY22 adjusted EPS of $3.22, down 14.4% Y/Y, beating the consensus of $2.97. Sales came in at $2.61 billion, a decline of 4% Y/Y, slightly lower than the Wall Street estimate of $2.63 billion. COVID-19 testing revenues fell 27.6% to $599 million, while Base…

Benzinga

Quest Diagnostics: Q1 Earnings Insights

Quest Diagnostics (NYSE:DGX) reported its Q1 earnings results on Thursday, April 21, 2022 at 06:45 AM. Here's what investors need to know about the announcement.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Quest Diagnostics's Earnings: A Preview

Quest Diagnostics (NYSE:DGX) is set to give its latest quarterly earnings report on Thursday, 2022-04-21. Here's what investors need to know before the announcement. Analysts estimate that Quest Diagnostics will report an earnings per share (EPS) of $2.97.

Benzinga

5 Value Stocks To Watch In The Healthcare Sector

What are Value Stocks?

Benzinga

Analyst Ratings For Quest Diagnostics

Quest Diagnostics (NYSE:DGX) has observed the following analyst ratings within the last quarter:

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 4, 2022

Upgrades

Get all your
news in one place.

100’s of premium titles.
One news app.

Axios

Positive drug tests for U.S. workers hit highest level since 2001

Overall positivity rate last year were up around 31% from all-time lows between 2010 and 2012.

Salon

Uninsured will now pay for COVID tests

Government funding cuts to key pandemic programs forced by GOP opposition arrive as progressives in Congress renew their push for Medicare for All.

Benzinga

Quest Diagnostics Secures CDC Contract To Support COVID-19 Research

The Centers for Disease Control and Prevention (CDC) has granted a contract to Quest Diagnostics Inc (NYSE:DGX) to perform testing and provide laboratory data analysis to help identify patterns in SARS-COV-2 seroprevalence on a multistate basis. Quest was awarded the contract following a competitive bid. The total contract value with all options is valued…

Benzinga

This Foreboding Sign Looms Over Quest Diagnostics's Chart

If history is any guide, there may be trouble ahead for shares of Quest Diagnostics (NYSE:DGX). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

Tribune News Service

Los trabajadores que usan cannabis legalmente aún pueden perder sus trabajos

Treinta y siete estados ahora le permiten a los adultos consumir marihuana con fines médicos, recreativos o ambos. Pero, en la mayoría de esos estados, las personas pueden ser despedidas o se les puede negar un trabajo si consumen cannabis en su tiempo libre.

Tribune News Service

Workers who legally use cannabis can still lose their jobs

Thirty-seven states now allow adults to use marijuana medically, recreationally or both. But in most of those states, people can be fired or denied a job for using cannabis in their free time.

Benzinga

What 8 Analyst Ratings Have To Say About Quest Diagnostics

Analysts have provided the following ratings for Quest Diagnostics (NYSE:DGX) within the last quarter:

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Centers for Disease Control and Prevention

Walgreens Boots Alliance

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.